Tempus Announces $275 Million in Funding

Tempus, a leader in artificial intelligence and precision medicine, today announced additional funding of approximately $275 million through a combination of equity from existing investors, which Tempus sold at the same price per share as its previous fundraising round, and debt financing from funds managed by Ares Management. In total, Tempus has now raised over $1.3 billion.    

The company is using the additional funds to scale its operations and capabilities, with a focus on building upon its disease agnostic platform designed to aggregate de-identified data and develop insights to power intelligent diagnostics. Tempus’ AI-enabled platform produces results that are contextualized for each specific patient and can help physicians personalize treatment decisions for their patients.

“In the last seven years, we’ve made great strides in developing and deploying smarter diagnostics not only in oncology, but neuropsychiatry, infectious disease, and cardiology,” said Eric Lefkofsky, Founder and CEO at Tempus. “We are committed to achieving our mission in applying AI to healthcare broadly with a focus on deploying solutions at scale that have real impact on patient care today and research in the future.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Related Content

View more
  • post image

    Revolutionizing Cardiac Care: AI-driven detection and treatment of critical heart valve disease at Boulder Community Health

    Discover how Tempus Next's AI-powered care pathway platform transformed patient outcomes by helping ensure timely, guideline-directed treatment for critical heart valve disease at Boulder Community Health

    Read more
  • post image

    ADCs in focus: The next generation of precision medicine in oncology

    Watch this engaging discussion as thought leaders explore the evolving landscape of antibody-drug conjugates (ADCs) in cancer therapeutics, including resistance mutations in first-gen ADCs, combination strategies with immune checkpoint inhibitors (ICIs), and next-gen targets and technologies. Tempus is dedicated to enhancing ADC development by offering comprehensive genomic profiling, multimodal de-identified real-world data (RWD), and AI-enabled solutions, informing target discovery and clinical trial optimization for more personalized therapies.

    Watch replay
  • post image

    Advancing transcriptional cancer therapies with Tempus’ comprehensive life science solutions

    Kronos Bio, a trailblazer in the biopharmaceutical industry, is dedicated to the discovery and development of novel therapies that target transcriptional regulation in cancer. Kronos turned to Tempus’ comprehensive suite of solutions to propel its principal asset from discovery to clinical trials.


    Wednesday, July 31 @ 11am CT

    Integrating Omics in R&D: A new era of biomedical research

    Join us as we explore how multi-omics is reshaping the research landscape. Gain valuable insights from industry leaders as we: dive into the integration of diverse omics data, from NGS to proteomics, in research; discuss the transformative role of multi-omics in understanding complex disease mechanisms; and explore how multi-omics is personalizing clinical research for precision medicine.

    Read more